AAV Gene Therapy Panel Shined Light On Safety Issues That Sponsors Have Downplayed – FDA’s Bryan

 
• By Sue Sutter
Transparent balls
An FDA panel meeting brought transparency to a host of safety issues that FDA believes gene therapy companies have downplayed. • Source: Alamy

More from Cell & Gene Therapies

More from Advanced Technologies